The combination showed an ORR of 33.3% in HNSCC and 20% in both melanoma and clear renal cell carcinoma, anti-PD-1-resistant tumors, thus showing promise in overcoming resistance to PD-1 blockade [177]. This evidence concerns the gene PDCD1 and melanoma.